Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
Carlos Doti, VP US Medical Affairs Oncology at AstraZeneca, shared on LinkedIn:
”As I reflect on another ASH, I’m reminded why this meeting is such a powerful close to the year – where science, collaboration and patient experiences come together to shape the future of hematology.
This year, I participated in two meaningful AstraZeneca events:
Moderating our annual Patient Advocacy Exchange panel with advocacy leaders focused on shared decision-making and patient navigation, discussing how to break down barriers and promote equitable access to care.
Hosting our first-ever AZHemeTalks – a live, pop-up series – at our booth, where I spoke with a clinical trial patient and her doctor about how treatment choices impact daily life.
The video here shows how we brought this activation to life through 4 expert panels focused on the treatment landscape in leukemia, lymphomas and multiple myeloma.”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome
-
Dec 18, 2025, 12:12Niraj Sharma: Can We Really Stop Anticoagulation After AF Ablation?